Rocket Lab's Tale of Two Timelines: Record Orders Versus a Bruised Chart

Rocket Lab's stock drops 58% from peak despite record launch contracts and $2.2B backlog, as Neutron delays fuel volatility.

Investors staring at Rocket Lab's price chart and investors reading its order book could be forgiven for thinking they are looking at two entirely different companies. The disconnect between the operational story and the stock's recent trajectory has rarely been wider.

The shares managed a 9.18 percent bounce on Thursday to 55.90 euros, a welcome reprieve after a brutal stretch that saw the stock shed 36.48 percent in a single month. Yet even with that rebound, the equity remains 58.22 percent below its May peak of 133.80 euros — a 52-week high that now feels like a distant memory. The whipsawing has been relentless: annualized volatility sits at roughly 96.64 percent, a figure that underscores just how much nerve this holding demands.

A Backlog That Keeps Growing

What makes the price action so puzzling is the flow of news coming out of the company itself. This week alone brought two significant developments. Rocket Lab secured the largest launch contract in its history — a multi-launch agreement with the US Space Force valued at 266 million dollars, covering at least twelve suborbital missions for missile defense testing, with initial flights expected as early as late 2026. The deal also expands the company's geographic footprint through a new launch site at the Pacific Spaceport Complex in Alaska.

That followed three additional launch orders from Japanese satellite operator iQPS, adding to a commercial pipeline that is building the kind of revenue visibility rarely seen in an industry where a single failed mission can upend an entire year's planning.

The order book tells an even more compelling story. At the end of the first quarter, Rocket Lab carried a backlog of 2.2 billion dollars, supported by more than 2 billion dollars in available liquidity. The company has also signed 36 new launch agreements — 31 for its workhorse Electron and HASTE vehicles, with five dedicated to the upcoming Neutron rocket. Management insists these are coming in without the need for discounting, a sign of pricing power that has not gone unnoticed.

The Neutron Question

At the heart of the valuation debate sits Neutron, the medium-lift rocket still in development. A tank failure has pushed the anticipated first flight to no earlier than the fourth quarter of 2026 — the second delay within a year, after the original target of late 2025 slipped. Founder Peter Beck has framed the additional qualification work as a matter of technical diligence rather than a threat to the business model, arguing the vehicle needs this step before its maiden voyage.

Demand, notably, has not cooled. The five dedicated Neutron contracts already on the books suggest customers remain confident in the vehicle's eventual arrival. But the financial impact will take time to materialize: the first flight is essentially a proof of capability, with meaningful revenue contributions from Neutron not expected until 2027 and 2028.

A Strategic Pivot Beyond Rockets

The recent volatility — and the stock's slide below all major moving averages — has obscured a more fundamental transformation. Late June brought the announcement of Rocket Lab's roughly 8 billion dollar acquisition of Iridium Communications, a move designed to shift the company beyond its "we just launch rockets" identity. Iridium's established L-band spectrum and recurring service fees position Rocket Lab as a provider of complete space systems, from launch vehicles to satellite services.

The logic is straightforward: the reliable Electron business funds the leap into the medium-payload class with Neutron, while acquisitions like Iridium secure higher-margin service revenue. The market has taken notice, valuing the company at approximately 35.11 billion euros and treating it as a credible challenger to established industry players.

Reading the Technicals

From a chart perspective, the stock recently spent time in deeply oversold territory. The 14-day RSI touched 36.2 — a level that often precedes a counter-move — though it has since climbed to 38.7, leaving the oversold zone while still sitting below the neutral midpoint. The current price remains 17.03 percent beneath the 200-day moving average of 67.37 euros, illustrating the ground that must be recovered to repair the long-term chart.

The longer-term picture offers some perspective. Over twelve months, Rocket Lab shares remain up 42.82 percent, and even after the recent slide, the year-to-date loss stands at a modest 6.18 percent. The 30-day window tells a harsher story at minus 34.43 percent, and the stock trades below both its 50-day and 200-day lines. Historical patterns suggest recoveries from full drawdowns have taken a median of roughly four months when they have come at all — though the deepest past decline, a 70 percent plunge during the 2022 inflation shock and Fed tightening cycle, shows the downside risk is real.

Advertisement

While Rocket Lab navigates the risks of delayed launches and volatile markets, workplace leaders face their own set of operational hazards — and the cost of getting them wrong can be just as punishing. Many employers underestimate the dangerous gaps in their safety documentation until an incident occurs. A free toolkit with 41 ready-to-use checklists and templates helps you document workplace risks properly and stay compliant. Download the free Risk Assessment Toolkit

The Analyst Gap

Wall Street remains notably optimistic despite the market's skittishness. The average analyst price target stands at 99.32 euros, implying upside of roughly 72 to 78 percent depending on the reference point. Such a wide gap typically signals one of two things: either extreme market skepticism about execution risk, or analysts pricing in Neutron's commercial ramp-up while the market hesitates.

Closing that gap will require near-flawless execution on two fronts: a successful Neutron first flight by the end of 2026 and smooth integration of the Iridium assets. Whether Rocket Lab can maintain its impeccable track record with core customers like iQPS while managing these far larger undertakings remains the key unknown. The stock's operational narrative and its price action are currently telling almost opposite stories — and in this cycle of speculative space investing, conviction is being tested less by analysis than by patience.